---
title: "Dapagliflozin for Hypertension: Efficacy, Mechanisms, and Clinical Considerations"
id: "pubmed-42826222"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42826222"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42826222/"
doi: "10.1080/10641963.2026.2731624"
published_at: "2026-10-02T21:47:41.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Dapagliflozin for Hypertension: Efficacy, Mechanisms, and Clinical Considerations
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42826222
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42826222/)
- **DOI:** [10.1080/10641963.2026.2731624](https://doi.org/10.1080%2F10641963.2026.2731624)
- **Published At:** 2026-10-02T21:47:41.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Hypertension remains a leading modifiable risk factor for cardiovascular disease and premature mortality worldwide; management is especially difficult in patients with type 2 diabetes (T2D), chronic kidney disease (CKD), or heart failure (HF). - **Dapagliflozin**, an **SGLT2 inhibitor**, is established in contemporary cardiorenal therapy and provides consistent **blood pressure**–lowering effects across clinical settings. - Observed BP reductions with dapagliflozin tend to be greater for **systolic BP** than **diastolic BP**; the physiological reasons for this differential response are not fully defined in the source. - Proposed mechanisms for antihypertensive effects include **osmotic diuresis and natriuresis**, weight loss, modulation of the sympathetic nervous system, increased uric acid excretion, and reduction of oxidative stress, inflammation, and vascular dysfunction. - Dapagliflozin shows generally good tolerability in studies, but long-term use can be limited by the risk of **genital infections**. - Current evidence supports dapagliflozin as an adjunctive **cardiorenal** agent that may offer additional BP lowering in patients with hypertension plus T2D, CKD, or HF, rather than replacing standard antihypertensive therapy. - The review calls for future hypertension-focused clinical trials to better define dapagliflozin’s role specifically in hypertension management. - Plain-language summary in the source highlights the global hypertension burden and frames dapagliflozin as offering supplementary BP benefits alongside cardiorenal protection while noting infection risk.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42826222/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42826222%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42826222/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42826222/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42826222/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42826222/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42826222/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42826222/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42826222%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42826222%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42826222/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42826222/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42826222/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42826222/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42826222/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42826222/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42826222/#abstract) * [ Plain language summary ](https://pubmed.ncbi.nlm.nih.gov/42826222/#plain-language-summary) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42826222/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42826222/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42826222/#substances) Title & authors Abstract Plain language summary Publication types MeSH terms Substances Review Clin Exp Hypertens Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Clin+Exp+Hypertens%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Clin+Exp+Hypertens%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42826222/) . 2026 Dec 31;48(1):2731624. doi: 10.1080/10641963.2026.2731624. Epub 2026 Oct 2. # Efficacy and mechanistic insights of dapagliflozin in hypertension management [Zhongbo Chen](https://pubmed.ncbi.nlm.nih.gov/?term=Chen+Z&cauthor_id=42826222)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42826222/#full-view-affiliation-1 "Department of Cardiology, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Cardiovascular Disease Research Institute of Chengdu, Chengdu, China."), [Wang Chunbin](https://pubmed.ncbi.nlm.nih.gov/?term=Chunbin+W&cauthor_id=42826222)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42826222/#full-view-affiliation-1 "Department of Cardiology, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Cardiovascular Disease Research Institute of Chengdu, Chengdu, China."), [Hanmei Zhang](https://pubmed.ncbi.nlm.nih.gov/?term=Zhang+H&cauthor_id=42826222)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42826222/#full-view-affiliation-2 "West China School of Medicine, Sichuan University, Chengdu, China."), [Ting Luo](https://pubmed.ncbi.nlm.nih.gov/?term=Luo+T&cauthor_id=42826222)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42826222/#full-view-affiliation-2 "West China School of Medicine, Sichuan University, Chengdu, China.")[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42826222/#full-view-affiliation-3 "National Clinical Research Center of Geriatrics, West China Hospital, Sichuan University, Chengdu, China."), [Jinhua Yan](https://pubmed.ncbi.nlm.nih.gov/?term=Yan+J&cauthor_id=42826222)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42826222/#full-view-affiliation-2 "West China School of Medicine, Sichuan University, Chengdu, China.")[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42826222/#full-view-affiliation-3 "National Clinical Research Center of Geriatrics, West China Hospital, Sichuan University, Chengdu, China.")[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42826222/#full-view-affiliation-4 "Department of Comprehensive Special Medical Services, International Medical Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.") Affiliations Expand ### Affiliations * 1 Department of Cardiology, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Cardiovascular Disease Research Institute of Chengdu, Chengdu, China. * 2 West China School of Medicine, Sichuan University, Chengdu, China. * 3 National Clinical Research Center of Geriatrics, West China Hospital, Sichuan University, Chengdu, China. * 4 Department of Comprehensive Special Medical Services, International Medical Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China. * PMID: **42826222** * DOI: [ 10.1080/10641963.2026.2731624 ](https://doi.org/10.1080/10641963.2026.2731624) Item in Clipboard Review # Efficacy and mechanistic insights of dapagliflozin in hypertension management Zhongbo Chen et al. Clin Exp Hypertens. 2026. Show details Display options Display options Format Abstract PubMed PMID Clin Exp Hypertens Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Clin+Exp+Hypertens%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Clin+Exp+Hypertens%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42826222/) . 2026 Dec 31;48(1):2731624. doi: 10.1080/10641963.2026.2731624. Epub 2026 Oct 2. ### Authors [Zhongbo Chen](https://pubmed.ncbi.nlm.nih.gov/?term=Chen+Z&cauthor_id=42826222)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42826222/#short-view-affiliation-1 "Department of Cardiology, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Cardiovascular Disease Research Institute of Chengdu, Chengdu, China."), [Wang Chunbin](https://pubmed.ncbi.nlm.nih.gov/?term=Chunbin+W&cauthor_id=42826222)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42826222/#short-view-affiliation-1 "Department of Cardiology, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Cardiovascular Disease Research Institute of Chengdu, Chengdu, China."), [Hanmei Zhang](https://pubmed.ncbi.nlm.nih.gov/?term=Zhang+H&cauthor_id=42826222)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42826222/#short-view-affiliation-2 "West China School of Medicine, Sichuan University, Chengdu, China."), [Ting Luo](https://pubmed.ncbi.nlm.nih.gov/?term=Luo+T&cauthor_id=42826222)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42826222/#short-view-affiliation-2 "West China School of Medicine, Sichuan University, Chengdu, China.")[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42826222/#short-view-affiliation-3 "National Clinical Research Center of Geriatrics, West China Hospital, Sichuan University, Chengdu, China."), [Jinhua Yan](https://pubmed.ncbi.nlm.nih.gov/?term=Yan+J&cauthor_id=42826222)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42826222/#short-view-affiliation-2 "West China School of Medicine, Sichuan University, Chengdu, China.")[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42826222/#short-view-affiliation-3 "National Clinical Research Center of Geriatrics, West China Hospital, Sichuan University, Chengdu, China.")[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42826222/#short-view-affiliation-4 "Department of Comprehensive Special Medical Services, International Medical Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.") ### Affiliations * 1 Department of Cardiology, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Cardiovascular Disease Research Institute of Chengdu, Chengdu, China. * 2 West China School of Medicine, Sichuan University, Chengdu, China. * 3 National Clinical Research Center of Geriatrics, West China Hospital, Sichuan University, Chengdu, China. * 4 Department of Comprehensive Special Medical Services, International Medical Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China. * PMID: **42826222** * DOI: [ 10.1080/10641963.2026.2731624 ](https://doi.org/10.1080/10641963.2026.2731624) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract Hypertension remains one of the leading modifiable risk factors for cardiovascular disease and premature mortality worldwide. Blood pressure (BP) management is particularly challenging in patients with coexisting type 2 diabetes (T2D), chronic kidney disease (CKD), or heart failure (HF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors have become an integral component of contemporary cardiorenal therapy and have consistently demonstrated additional BP-lowering effects across diverse clinical settings. This narrative review synthesizes the current clinical evidence regarding the antihypertensive effects of dapagliflozin and summarizes the biological mechanisms that may contribute to these effects, including osmotic diuresis and natriuresis, weight reduction, modulation of the sympathetic nervous system, enhanced uric acid excretion, and attenuation of oxidative stress, inflammation, and vascular dysfunction. Across clinical studies, reductions in systolic BP (SBP) generally exceed those in diastolic BP (DBP), although the physiological basis underlying this differential response remains incompletely understood. Dapagliflozin has demonstrated good tolerability and antihypertensive effects in clinical applications, its long-term use may be limited by the risk of genital infections. Collectively, the available evidence supports dapagliflozin as a cardiorenal therapeutic agent that may provide additional BP-lowering benefits in patients with hypertension and concomitant T2D, CKD, or HF, rather than as a substitute for conventional antihypertensive therapy. Future hypertension-focused clinical studies are warranted to further define its role in hypertension management. **Keywords:** Dapagliflozin; SGLT2 inhibitor; blood pressure; cardiorenal disease; hypertension. ## Plain language summary Global hypertension crisis: affects over a billion adults, major risk for heart disease and premature death.Dapagliflozin benefits: additional blood pressure benefits complement its cardiorenal protection.Dapagliflozin risks: potential for genital infections, but offers a new hypertension treatment option. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Publication types * Review Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Review%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Review) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42826222/) ## MeSH terms * Antihypertensive Agents* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antihypertensive+Agents%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antihypertensive+Agents) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42826222/) * Benzhydryl Compounds* / pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Benzhydryl+Compounds%2Fpharmacology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Benzhydryl+Compounds) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42826222/) * Benzhydryl Compounds* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Benzhydryl+Compounds%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Benzhydryl+Compounds) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42826222/) * Blood Pressure* / drug effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Blood+Pressure%2Fdrug+effects%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Blood+Pressure) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42826222/) * Diabetes Mellitus, Type 2 / complications Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Diabetes+Mellitus%2C+Type+2%2Fcomplications%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Diabetes+Mellitus%2C+Type+2) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42826222/) * Glucosides* / pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Glucosides%2Fpharmacology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Glucosides) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42826222/) * Glucosides* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Glucosides%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Glucosides) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42826222/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42826222/) * Hypertension* / complications Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Hypertension%2Fcomplications%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Hypertension) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42826222/) * Hypertension* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Hypertension%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Hypertension) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42826222/) * Hypertension* / physiopathology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Hypertension%2Fphysiopathology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Hypertension) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42826222/) * Sodium-Glucose Transporter 2 Inhibitors* / pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Sodium-Glucose+Transporter+2+Inhibitors%2Fpharmacology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Sodium-Glucose+Transporter+2+Inhibitors) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42826222/) * Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Sodium-Glucose+Transporter+2+Inhibitors%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Sodium-Glucose+Transporter+2+Inhibitors) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42826222/) ## Substances * dapagliflozin Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22dapagliflozin%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22dapagliflozin%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42826222/) * Benzhydryl Compounds Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Benzhydryl+Compounds%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](
## Related Clinical Research

- [SGLT2 inhibitors and urinary tract infection risk: trial-level meta-analysis across T2D, HF, and C](https://medichelpline.com/clinical-feed/pubmed-42566081.md) (DOI: 10.1007/s40199-026-00637-7)
- [Safiglipron vs dapagliflozin in type 2 diabetes: phase 3 randomized double-blind OUTSTAND-2 results](https://medichelpline.com/clinical-feed/nature-0-oral-small-molecule-glp-1ra-safiglipron-versus-dapagliflozin-in-type-2-diabetes.md)
- [SGLT2 inhibitors vs GLP-1 RAs and osteoarthritis risk in type 2 diabetes: a multi-institutional co](https://medichelpline.com/clinical-feed/plos-one-16-comparative-effects-of-sglt2-inhibitors-and-glp-1-receptor-agonists-on.md)
- [Prevalence, risk factors, and renoprotective treatment gaps in chronic kidney disease among tertia](https://medichelpline.com/clinical-feed/bmj-open-9-prevalence-risk-factors-and-renoprotective-treatment-of-chronic-kidney-disease.md)
- [Comparing BMI, Waist Circumference, and BRI for Predicting ASCVD, AF, and Mortality in 1.2M Koreans](https://medichelpline.com/clinical-feed/plos-one-14-prognostic-associations-of-anthropometric-indices-with-major-health-outcomes-a.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.